Lazertinib - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Lazertinib

Brand Name:

Lazcluze

Strength:

80mg, 240mg

HCPCS:

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Tyrosine Kinase Inhibitor

Minor Drug Class:

EGFR

Oral (Y/N):

Yes

FDA Approval Year:

2024

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use